Home Newsfeeds HC Wainwright & Co. Maintains Neutral on Terns Pharma, Raises Price Target to $7

HC Wainwright & Co. Maintains Neutral on Terns Pharma, Raises Price Target to $7

HC Wainwright & Co. analyst Ed Arce maintains Terns Pharma (NASDAQ:TERN) with a Neutral and raises the price target from $6 to $7.

byBenzinga Newsdesk

December 29, 2022

1 minute read

HC Wainwright & Co. analyst Ed Arce maintains Terns Pharma (NASDAQ:TERN) with a Neutral and raises the price target from $6 to $7.

Stifel Downgrades Twilio to Hold, Lowers Price Target to $90

By Benzinga Newsdesk

August 5, 6:13 AM

Stifel analyst Parker Lane downgrades Twilio (NYSE:TWLO) from Buy to Hold and lowers the price target from $200 to $90.

TWLO

Jim Cramer Says This Tech Stock Up More Than 60% In 2023 Is An ‘Expensive Stock, But It Is A Good One’

By Lisa Levin

November 2, 8:48 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Trade Desk, Inc.

ADNT

European Central Bank Raises The Interest Rate By 75 Basis Points As Expected

By Anusuya Lahiri

September 8, 8:31 AM

ECB has raised the interest rate by 75 bps to 1.25%, in line with the expectations.

FLEE

Movano Health Announces Blood Pressure Partnership Forum Following Significant Response To Accuracy Achievement

By Benzinga Newsdesk

December 12, 1:01 PM

Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that following the successful results of its recent blood pressure clinical trial it will be holding in person demonstrations of

MOVE

HC Wainwright & Co. Maintains Neutral on Terns Pharma, Raises Price Target to $7

Related Posts

Stifel Downgrades Twilio to Hold, Lowers Price Target to $90

Jim Cramer Says This Tech Stock Up More Than 60% In 2023 Is An ‘Expensive Stock, But It Is A Good One’

European Central Bank Raises The Interest Rate By 75 Basis Points As Expected

Movano Health Announces Blood Pressure Partnership Forum Following Significant Response To Accuracy Achievement